PacketFabric Democratizes Cloud Connectivity Pricing
9.12.2020 17:15:00 EET | Business Wire | Press release
PacketFabric, an innovator of on-demand connectivity to the secure, private internet, today announced it launched flat rate pricing for hybrid cloud connectivity across the U.S. and Europe. With this innovative pricing strategy, PacketFabric continues to lead the market disruption of networking and cloud computing.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201209005337/en/
“They say you can’t have it good, fast and cheap, but now you can have all three with PacketFabric’s flat rate, cloud connectivity pricing,” said PacketFabric CEO, Dave Ward. (Graphic: Business Wire)
PacketFabric’s new democratized pricing is $100 per month for hosted hybrid cloud connections up to 1Gbps, for both metro and long-haul capacity in the United States and Europe. With this new pricing strategy, PacketFabric is making cloud connectivity egalitarian across the tech landscape.
“Cloud is the future, and it shouldn’t be exclusive,” said PacketFabric CEO Dave Ward. “That’s why we sought a way to democratize it. Now with PacketFabric’s flat rate pricing, companies from emerging businesses to large enterprises can have affordable access to the cloud.”
According to Gartner, “cost optimization will be crucial to drive cloud adoption, and by 2024, all legacy applications will be migrated to public cloud infrastructure.”
“They say you can’t have it good, fast and cheap, but now you can have all three with PacketFabric’s flat rate, cloud connectivity pricing,” continued Ward. “We’ve been disrupting the market since we launched PacketFabric’s Network-as-a-Service (NaaS) platform in 2017, and we continue to lead the way forward.”
PacketFabric’s NaaS orchestrates and guarantees connectivity between collocation facilities, clouds, and offers private network interconnection across the globe. The NaaS platform is private, secure, reliable and scalable, plus it’s fully redundant. PacketFabric is a women-founded technology start-up, launched by industry veterans Jezzibell Gilmore, PacketFabric’s Chief Commercial Officer, and Anna Claiborne, Senior Vice President of Product and Engineering for PacketFabric.
Ward, a prolific technologist, expands on PacketFabric’s strategy in his recent blog post, “Democratizing Access to the Cloud, Disrupting the Business of Getting to the Cloud.”
About PacketFabric
PacketFabric redefines how the enterprise moves data by automating network connectivity services. Leveraging an entirely automated SDN-based network architecture and the latest in optical and packet switching technology, PacketFabric enables dynamic, real-time connectivity services between more than hundreds of premier colocation facilities across many global markets. The PacketFabric Network-as-a-Service (NaaS) platform delivers simple, cost-effective, and scalable network deployment via its advanced Application Program Interface (API) and web portal. PacketFabric was named one of the “10 Hottest Networking Startups in 2020” by CRN and a 2020 “Cool Vendor in Enhanced Internet Services and Cloud Connectivity” by Gartner. PacketFabric investors include NantWorks and Digital Alpha Advisors. For more information, visit packetfabric.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201209005337/en/
Contact information
Media Contact:
Lauren de la Fuente
VP Marketing, PacketFabric
310-283-8488
lauren.delafuente@packetfabric.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 14:30:00 EEST | Press release
Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European Society for Medical Oncology (ESMO) Congress, showed the study met its dual primary endpoints of overall survival (OS) and progression-free survival (PFS). Gastric cancer is a leading cause of cancer-related death worldwide, and outcomes are particularly poor once the disease is advanced.1 Because treatment options are limited for people whose cancer continues to progress after multiple therapies, there is a significant need for new targeted therapies.2 CLDN18.2, a protein found at abnormally high levels on the surface of certain cancer cells, has emerged as a key biomarke
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom